


# PRODUCT INFORMATION



## Citicoline (sodium salt)

Item No. 14629

**CAS Registry No.:** 33818-15-4  
**Formal Name:** P'-[2-(trimethylammonio)ethyl] ester-cytidine 5'-(trihydrogen diphosphate)-inner, monosodium salt  
**Synonyms:** Cytidine 5'-diphosphocholine, Flussoresx, Gerolin, Logan, Neurotron, Sinkron  
**MF:** C<sub>14</sub>H<sub>25</sub>N<sub>4</sub>O<sub>11</sub>P<sub>2</sub> • Na  
**FW:** 510.3  
**Purity:** ≥95%  
**UV/Vis.:** λ<sub>max</sub>: 274 nm  
**Supplied as:** A crystalline solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Citicoline (sodium salt) is supplied as a crystalline solid. Aqueous solutions of citicoline (sodium salt) can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of citicoline (sodium salt) in PBS (pH 7.2) is approximately 10 mg/ml. We do not recommend storing the aqueous solution for more than one day.

### Description

Citicoline is an endogenous intermediate in the synthesis of phosphatidylcholine, the major phospholipid in eukaryotic cells.<sup>1</sup> It also serves as a choline donor in the biosynthesis of the neurotransmitter acetylcholine. Citicoline demonstrates protective effects in cerebral ischemia, traumatic brain injury, and memory disorders.<sup>2</sup> Exogenous administration of citicholine to rodents (500 mg/kg i.p. immediately after ischemia and at 3-h reperfusion) has been shown to stimulate the synthesis of phosphatidylcholine, sphingomyelin, and cardiolipin and to attenuate the release of arachidonic acid and the accumulation of ceramide.<sup>3</sup>

### References

1. McMaster, C.R., and Bell, R.M. Phosphatidylcholine biosynthesis via the CDP-choline pathway in *Saccharomyces cerevisiae*. *J. Biol. Chem.* **269**(20), 14776-14783 (1994).
2. Dávalos, A. and Secades, J. Citicoline preclinical and clinical update 2009-2010. *Stroke* **42**(1), 36-39 (2011).
3. Rao, M., Hatcher, J.F., and Dempsey, R.J. Lipid alterations in transient forebrain ischemia: Possible new mechanisms of CDP-choline neuroprotection. *J. Neurochem.* **75**(6), 2528-2535 (2000).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/20/2022

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897

[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM